Literature DB >> 22147894

Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia.

Jason LeGrand1, Eun Sung Park, Hongyang Wang, Shalu Gupta, James D Owens, Patrick J Nelson, Wendy DuBois, Thomas Bair, Siegfried Janz, J Frederic Mushinski.   

Abstract

Tumor progression usually proceeds through several sequential stages, any of which could be targets for interrupting the progression process if one understood these steps at the molecular level. We extracted nascent plasma cell tumor (PCT) cells from within inflammatory oil granulomas (OG) isolated from IP pristane-injected BALB/c.iMyc(Eμ) mice at 5 different time points during tumor progression. We used laser capture microdissection to collect incipient PCT cells and analyzed their global gene expression on Affymetrix Mouse Genome 430A microarrays. Two independent studies were performed with different sets of mice. Analysis of the expression data used ANOVA and Bayesian estimation of temporal regulation. Genetic pathway analysis was performed using MetaCore (GeneGo) and IPA (Ingenuity). The gene expression profiles of PCT samples and those of undissected OG samples from adjacent sections showed that different genes and pathways were mobilized in the tumor cells during tumor progression, compared with their stroma. Our analysis implicated several genetic pathways in PCT progression, including biphasic (up- and then down-regulation) of the Spp1/osteopontin-dependent network and up-regulation of mRNA translation/protein synthesis. The latter led to a biologic validation study that showed that the AMPK-activating diabetes drug, metformin, was a potent specific PCT inhibitor in vitro.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147894      PMCID: PMC3271714          DOI: 10.1182/blood-2011-06-363887

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Co-expression of osteopontin and CD44v9 in gastric cancer.

Authors:  T Ue; H Yokozaki; Y Kitadai; S Yamamoto; W Yasui; T Ishikawa; E Tahara
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

Review 2.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

3.  Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas.

Authors:  A B Tuck; F P O'Malley; H Singhal; K S Tonkin; J F Harris; D Bautista; A F Chambers
Journal:  Arch Pathol Lab Med       Date:  1997-06       Impact factor: 5.534

4.  A stromal cell line from myeloid long-term bone marrow cultures can support myelopoiesis and B lymphopoiesis.

Authors:  L S Collins; K Dorshkind
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

5.  Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.

Authors:  A B Tuck; D M Arsenault; F P O'Malley; C Hota; M C Ling; S M Wilson; A F Chambers
Journal:  Oncogene       Date:  1999-07-22       Impact factor: 9.867

6.  Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas.

Authors:  S R Amoroso; N Huang; A B Roberts; M Potter; J J Letterio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

7.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

8.  Osteopontin expression in lung cancer.

Authors:  A F Chambers; S M Wilson; N Kerkvliet; F P O'Malley; J F Harris; A G Casson
Journal:  Lung Cancer       Date:  1996-11       Impact factor: 5.705

9.  Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.

Authors:  Therese Standal; Henrik Hjorth-Hansen; Thomas Rasmussen; Inger Marie S Dahl; Stig Lenhoff; Anne-Tove Brenne; Carina Seidel; Vadim Baykov; Anders Waage; Magne Børset; Anders Sundan; Oyvind Hjertner
Journal:  Haematologica       Date:  2004-02       Impact factor: 9.941

10.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

View more
  4 in total

1.  Impact of metformin on the progression of MGUS to multiple myeloma.

Authors:  Ben Boursi; Ronac Mamtani; Yu-Xiao Yang; Brendan M Weiss
Journal:  Leuk Lymphoma       Date:  2016-10-05

2.  Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.

Authors:  V S Tompkins; R Sompallae; T R Rosean; S Walsh; M Acevedo; A L Kovalchuk; S-S Han; X Jing; C Holman; J E Rehg; S Herms; J S Sunderland; H C Morse; S Janz
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

3.  Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity.

Authors:  Ming-Ling Chang; Chia-Jung Kuo; Hsin-Chih Huang; Yin-Yi Chu; Cheng-Tang Chiu
Journal:  PLoS One       Date:  2016-11-21       Impact factor: 3.240

4.  (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.

Authors:  K Duncan; T R Rosean; V S Tompkins; A Olivier; R Sompallae; F Zhan; G Tricot; M R Acevedo; L L B Ponto; S A Walsh; L T Tygrett; A J Berger; T Waldschmidt; H C Morse; J J Sunderland; S Janz
Journal:  Blood Cancer J       Date:  2013-11-29       Impact factor: 11.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.